+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phacilitate, Partnering For Vaccine Emerging Markets June 10-11 2013, Berlin session: Brazil and Argentina--Profiling Vaccine Demand, Supply and Aspirations



Phacilitate, Partnering For Vaccine Emerging Markets June 10-11 2013, Berlin session: Brazil and Argentina--Profiling Vaccine Demand, Supply and Aspirations



Human Vaccines and Immunotherapeutics 9(9): 2019-2021




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054952647

Download citation: RISBibTeXText

PMID: 23896587

DOI: 10.4161/hv.25946


Related references

Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets. Human Vaccines and Immunotherapeutics 9(9): 2022-2024, 2013

Estimating The Supply And Demand Of Butantan Dengue Vaccine In Brazil. Value in Health 18(7): A807, 2015

Estimating potential demand and supply of dengue vaccine in Brazil. Human Vaccines 7(7): 776-780, 2011

Seasonal and pandemic influenza vaccine: demand, supply and vaccine availability. Vaccine 32(52): 7037-7039, 2014

Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon. Human Vaccines & Immunotherapeutics 9(4): 924-927, 2014

How will diagnostics create new opportunities for prophylactic and therapeutic vaccines?: 2011 Phacilitate Vaccine Forum, Washington DC Day 2, afternoon plenary session—January 25, 2011. Human Vaccines 7(6): 607-609, 2011

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. Vaccine 33(16): 1987-1992, 2015

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013. Vaccine 32(48): 6499-6504, 2014

Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon. Human Vaccines & Immunotherapeutics 9(4): 928-931, 2014

Public Health And Economic Impact of A Quadrivalent Influenza Vaccine In Comparison to The Trivalent Influenza Vaccine In Brazil Over The Period Of 2010 - 2013. Value in Health 18(7): A578-A579, 2015

A key for successful development of flu vaccines: public-private collaboration--the Barcelona Vaccine Forum, Phacilitate, the Fira Palace Barcelona Spain, 21-23 June, 2010, the meeting report. Human Vaccines 6(12): 966-969, 2010

Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Biologicals 37(3): 165-168, 2009

Is there enough vaccine to eradicate measles? An integrated analysis of measles-containing vaccine supply and demand. Journal of Infectious Diseases 204(Suppl. 1): S62-S70, 2011

Determining demand, supply, and pricing for emerging markets based on disruptive process technologies. Technological Forecasting and Social Change 71(1-2): 105-120, 2004

A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market. Journal of Infectious Diseases 216(Suppl_1): S33-S39, 2017